GlassScriptPhysician profile
Stephen Fw Cavanah
NPI 1427045723
$3,370.56
in general payments reported to CMS, 2019-2025
27 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,714 · 2020: $703 · 2021: $94.38 · 2022: $131 · 2023: $488 · 2024: $115 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.59 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $492.16 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $438.19 | 2019-2020 | |
| Medtronic, INC. | $341.72 | 2021-2023 | Minimed 780g |
| Insulet Corporation | $311.89 | 2019-2024 | Omnipod |
| Medtronic Minimed, INC. | $245.14 | 2019-2020 | |
| Dexcom, INC. | $202.14 | 2019-2023 | Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $180.73 | 2019-2023 | |
| Amarin Pharma, INC. | $168.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.35 | 2019-2020 | |
| Lilly USA, LLC | $140.09 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $124.70 | 2025 | Yorvipath |
| Abbott Laboratories | $97.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.05 | 2019-2020 | |
| Abbvie INC. | $56.90 | 2019-2020 | |
| Shire North American Group INC | $53.96 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $45.37 | 2019 | |
| Antares Pharma, INC. | $40.82 | 2019-2020 | |
| Lifescan, INC. | $38.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.65 | 2019-2020 | |
| Ibsa Pharma INC. | $29.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.82 | 2019-2020 | |
| Amgen INC. | $19.74 | 2019 | |
| Therapeuticsmd, INC. | $16.65 | 2019 | |
| Radius Health, INC. | $14.52 | 2023 | |
| Companion Medical, INC. | $12.02 | 2019 | |
| Horizon Therapeutics Plc | $11.95 | 2020 | |
| Eisai INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cavanah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.